Benitec Biopharma Inc.
BNTC
$11.50
-$0.18-1.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -96.12% | -111.06% | -84.41% | -32.24% | -8.25% |
| Total Depreciation and Amortization | 30.88% | 20.17% | 15.45% | 9.82% | 4.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 727.99% | 1,908.68% | 2,169.19% | 1,065.01% | 795.08% |
| Change in Net Operating Assets | 38.81% | -2,743.37% | -332.45% | 484.57% | -164.52% |
| Cash from Operations | 15.28% | -15.15% | -21.57% | 7.61% | -20.39% |
| Capital Expenditure | 91.10% | 89.94% | 89.94% | 90.00% | -19,000.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 91.10% | 89.94% | 89.94% | 90.00% | -19,000.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 77.84% | -6.98% | 10.70% | 167.02% | 167.02% |
| Repurchase of Common Stock | -23,156.41% | -23,156.41% | -23,156.41% | -23,156.41% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -192.90% | 20.80% | 60.64% | 1,280.00% | 1.15% |
| Cash from Financing | 62.30% | -20.95% | 3.61% | 286.34% | 184.71% |
| Foreign Exchange rate Adjustments | -162.33% | 255.41% | 712.50% | 811.11% | 655.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.76% | -36.50% | -3.12% | 1,078.90% | 489.17% |